JPWO2020018973A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018973A5 JPWO2020018973A5 JP2021503023A JP2021503023A JPWO2020018973A5 JP WO2020018973 A5 JPWO2020018973 A5 JP WO2020018973A5 JP 2021503023 A JP2021503023 A JP 2021503023A JP 2021503023 A JP2021503023 A JP 2021503023A JP WO2020018973 A5 JPWO2020018973 A5 JP WO2020018973A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- amino acid
- acid sequence
- cancer
- cytoplasmic signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 230000001086 cytosolic effect Effects 0.000 claims description 26
- 230000011664 signaling Effects 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 claims description 12
- 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- -1 CD3-ζ Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700942P | 2018-07-20 | 2018-07-20 | |
| US62/700,942 | 2018-07-20 | ||
| PCT/US2019/042707 WO2020018973A1 (en) | 2018-07-20 | 2019-07-19 | Anti-lypd3 car t-cell therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530238A JP2021530238A (ja) | 2021-11-11 |
| JPWO2020018973A5 true JPWO2020018973A5 (https=) | 2022-07-26 |
| JP2021530238A5 JP2021530238A5 (https=) | 2022-07-26 |
Family
ID=69164634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503023A Pending JP2021530238A (ja) | 2018-07-20 | 2019-07-19 | がんの処置のための抗ｌｙｐｄ３ ｃａｒ ｔ細胞療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210309711A1 (https=) |
| EP (1) | EP3823992B1 (https=) |
| JP (1) | JP2021530238A (https=) |
| KR (1) | KR20210063319A (https=) |
| CN (1) | CN112955466A (https=) |
| AU (1) | AU2019305223A1 (https=) |
| CA (1) | CA3106967A1 (https=) |
| SG (1) | SG11202100571TA (https=) |
| WO (1) | WO2020018973A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| PT2510012T (pt) * | 2009-12-09 | 2017-07-13 | Bayer Pharma AG | Anticorpos anti-c4.4a e utilizações dos mesmos |
| WO2014160627A1 (en) * | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| CA3289997A1 (en) * | 2015-09-20 | 2026-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use |
| CN105132575B (zh) * | 2015-09-28 | 2020-03-27 | 固安博健生物技术有限公司 | 骨质疏松症的分子标志物及其应用 |
| GB201518136D0 (en) * | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
| EP3454870A4 (en) * | 2016-05-12 | 2020-03-04 | Adicet Bio Inc. | METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF |
| BR112018074453A2 (pt) * | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| CN106119405B (zh) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用 |
| EP3759225A1 (en) * | 2018-03-02 | 2021-01-06 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
-
2019
- 2019-07-19 JP JP2021503023A patent/JP2021530238A/ja active Pending
- 2019-07-19 CN CN201980061125.6A patent/CN112955466A/zh active Pending
- 2019-07-19 WO PCT/US2019/042707 patent/WO2020018973A1/en not_active Ceased
- 2019-07-19 CA CA3106967A patent/CA3106967A1/en active Pending
- 2019-07-19 SG SG11202100571TA patent/SG11202100571TA/en unknown
- 2019-07-19 US US17/261,488 patent/US20210309711A1/en not_active Abandoned
- 2019-07-19 EP EP19838801.9A patent/EP3823992B1/en not_active Revoked
- 2019-07-19 KR KR1020217004654A patent/KR20210063319A/ko not_active Ceased
- 2019-07-19 AU AU2019305223A patent/AU2019305223A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| US11478548B2 (en) | Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapy | |
| KR20220145374A (ko) | 신규 키메라 항원 수용체 및 그 용도 | |
| JP2020517295A5 (https=) | ||
| JP2020533958A5 (https=) | ||
| JP2022501043A5 (https=) | ||
| JP2019525956A5 (https=) | ||
| WO2022012591A1 (zh) | 用于同种异体移植的工程化免疫细胞 | |
| JP2021532742A5 (https=) | ||
| JPWO2021102337A5 (https=) | ||
| WO2021147929A1 (zh) | 多链嵌合抗原受体及其用途 | |
| EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| CA3189677A1 (en) | Chimeric molecules providing targeted costimulation for adoptive cell therapy | |
| JPWO2020061498A5 (https=) | ||
| EP4613781A1 (en) | Immune rejection-resistant engineered cell | |
| EP4502159A1 (en) | Engineered immune cell with ciita gene knock-out and use thereof | |
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JPWO2020020359A5 (https=) | ||
| EP4186929A1 (en) | Novel co-stimulatory domain and uses thereof | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| JP2021530238A5 (https=) | ||
| JPWO2020018973A5 (https=) | ||
| US20220315931A1 (en) | Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene | |
| JPWO2021211948A5 (https=) | ||
| AU2024217219A1 (en) | Function-enhanced cell therapy |